To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 28, 2022

Primary Completion Date

May 30, 2024

Study Completion Date

September 30, 2024

Conditions

Gastric Cancer

Interventions

DRUG

RC48-ADC

RC48 for injection is a novel antibody-drug conjugate, with a her-2-targeting antibody and a microtube inhibitor

DRUG

RC98

RC98 is a recombinant humanized IgG1 monoclonal antibody targeting programmed cell death-Ligand 1 (PD-L1)

Trial Locations (1)

RECRUITING

Remegen, Beijing

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY